- Home
- KSS vs ETNB Comparison
KSS vs ETNB Comparison
Compare KSS & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KSS
- ETNB
- Stock Information
- Founded
- KSS 1962
- ETNB 2018
- Country
- KSS United States
- ETNB United States
- Employees
- KSS N/A
- ETNB N/A
- Industry
- KSS Department/Specialty Retail Stores
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- KSS Consumer Discretionary
- ETNB Health Care
- Exchange
- KSS Nasdaq
- ETNB Nasdaq
- Market Cap
- KSS 1.9B
- ETNB 2.2B
- IPO Year
- KSS 1992
- ETNB 2019
- Fundamental
- Price
- KSS $15.93
- ETNB $14.84
- Analyst Decision
- KSS Sell
- ETNB Buy
- Analyst Count
- KSS 14
- ETNB 10
- Target Price
- KSS $11.88
- ETNB $22.31
- AVG Volume (30 Days)
- KSS 4.3M
- ETNB 6.2M
- Earning Date
- KSS 11-25-2025
- ETNB 11-07-2025
- Dividend Yield
- KSS 3.14%
- ETNB N/A
- EPS Growth
- KSS N/A
- ETNB N/A
- EPS
- KSS 1.86
- ETNB N/A
- Revenue
- KSS $15,886,000,000.00
- ETNB N/A
- Revenue This Year
- KSS N/A
- ETNB N/A
- Revenue Next Year
- KSS N/A
- ETNB N/A
- P/E Ratio
- KSS $8.55
- ETNB N/A
- Revenue Growth
- KSS N/A
- ETNB N/A
- 52 Week Low
- KSS $6.04
- ETNB $4.16
- 52 Week High
- KSS $21.39
- ETNB $15.06
- Technical
- Relative Strength Index (RSI)
- KSS 49.92
- ETNB 76.55
- Support Level
- KSS $16.14
- ETNB $14.74
- Resistance Level
- KSS $17.15
- ETNB $14.85
- Average True Range (ATR)
- KSS 0.83
- ETNB 0.06
- MACD
- KSS 0.02
- ETNB -0.18
- Stochastic Oscillator
- KSS 61.57
- ETNB 76.92
About KSS Kohl's Corporation
Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).